Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Net Income (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed Net Income for 3 consecutive years, with -$30.1 million as the latest value for Q4 2025.

  • Quarterly Net Income fell 26.46% to -$30.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$35.5 million through Dec 2025, up 30.57% year-over-year, with the annual reading at -$35.5 million for FY2025, 30.48% up from the prior year.
  • Net Income hit -$30.1 million in Q4 2025 for Immunocore Holdings, down from -$196000.0 in the prior quarter.
  • In the past five years, Net Income ranged from a high of $8.7 million in Q3 2024 to a low of -$30.1 million in Q4 2025.
  • Historically, Net Income has averaged -$11.8 million across 3 years, with a median of -$14.3 million in 2023.
  • Biggest five-year swings in Net Income: surged 859.49% in 2024 and later crashed 102.25% in 2025.
  • Year by year, Net Income stood at -$19.7 million in 2023, then fell by 20.48% to -$23.8 million in 2024, then dropped by 26.46% to -$30.1 million in 2025.
  • Business Quant data shows Net Income for IMCR at -$30.1 million in Q4 2025, -$196000.0 in Q3 2025, and -$10.3 million in Q2 2025.